Connect with us

Published

on

Alex Zhavoronkov, left, founder and CEO of Insilico Medicine, and Feng Ren, co-CEO and chief scientific officer, at the company’s robotics lab in Suzhou, China.

Source: Insilico Medicine

The first drug fully generated by artificial intelligence entered clinical trials with human patients this week.

Insilico Medicine, a Hong Kong-based biotech startup with more than $400 million in funding, created the drug, INS018_055, as a treatment for idiopathic pulmonary fibrosis, a chronic disease that causes scarring in the lungs. The condition, which has increased in prevalence in recent decades, currently affects about 100,000 people in the U.S. and can lead to death within two to five years if untreated, according to the National Institutes of Health. 

“It is the first fully generative AI drug to reach human clinical trials, and specifically Phase II trials with patients,” Alex Zhavoronkov, founder and CEO of Insilico Medicine, told CNBC. “While there are other AI-designed drugs in trials, ours is the first drug with both a novel AI-discovered target and a novel AI-generated design.” 

The discovery process for the new drug began in 2020, with hopes to create a “moonshot” medicine to overcome challenges with current treatments for the condition, which mostly focus on slowing progression and can cause uncomfortable side effects, Zhavoronkov said.

He added that Insilico has chosen to focus on IPF in part because of the condition’s implications in aging, but the company has two other drugs partially generated by AI in the clinical stage. One is a Covid-19 drug in phase one clinical trials, and the other is a cancer drug, specifically a “USP1 inhibitor for the treatment of solid tumors,” that recently received FDA approval to initiate clinical trials.

“When this company was launched, we were focused on algorithms — developing the technology that could discover and design new molecules,” Zhavoronkov said. “I never imagined in those early days that I would be taking my own AI drugs into clinical trials with patients. But we realized that in order to validate our AI platform, we needed to not only design a new drug for a new target, but bring it into clinical trials to prove that our technology worked.” 

The IPF drug’s current study is a randomized, double-blind, placebo-controlled trial taking place over 12 weeks in China, and Insilico has plans to expand the testing population to 60 subjects at 40 sites in the U.S. and China. If the current phase two study is successful, it will go on to another study with a larger cohort, and then potentially reach phase three studies with hundreds of participants. 

“We expect to have results from the current Phase II trial next year,” Zhavoronkov said, adding that it’s difficult to predict exact timing for future phases, especially since the disease is relatively rare and patients must fulfill specific criteria. He added, “We are optimistic that this drug will be ready for market, and reach patients who may benefit from it, in the next few years.” 

Continue Reading

Technology

Peter Thiel just bought a big stake in Tom Lee’s ether company and the shares are surging

Published

on

By

Peter Thiel just bought a big stake in Tom Lee's ether company and the shares are surging

Peter Thiel, president and founder of Clarium Capital Management LLC, holds hundred dollars bills as he speaks during the Bitcoin 2022 conference in Miami, Florida, U.S., on Thursday, April 7, 2022. 

Eva Marie Uzcategui | Bloomberg | Getty Images

Stock Chart IconStock chart icon

hide content

Bitmine (BMNR) 1-month

The current wave of interest in Ethereum and related assets follows an announcement by Robinhood that it will enable trading of tokenized U.S. stocks and ETFs across Europe, and a groundswell of interest in stablecoins throughout June following Circle’s wildly successful IPO and ongoing progress in Congress on the Senate’s proposed stablecoin bill, the GENIUS Act.

The price of ether itself also continued its rally, up more than 4% Wednesday. The coin has doubled in price in the past three months.

Thiel is a venture capitalist and hedge fund manager best known as a cofounder of both PayPal and Palantir and an early investor in Facebook. Founders Fund was an investor in Tagomi, the crypto brokerage acquired by Coinbase in 2020, and Polymarket, the prediction market built on Ethereum.

Don’t miss these cryptocurrency insights from CNBC Pro:

Continue Reading

Technology

Nvidia CEO Jensen Huang sells another $37 million worth of stock

Published

on

By

Nvidia CEO Jensen Huang sells another  million worth of stock

NVIDIA founder and CEO Jensen Huang speaks during the NVIDIA GTC Paris keynote, part of the 9th edition of the VivaTech technology startup and innovation fair, held at the Dôme de Paris in the Porte de Versailles exhibition center in Paris on June 11, 2025.

Mustafa Yalcin | Anadolu | Getty Images

Nvidia CEO Jensen Huang sold another 225,000 shares of the chipmaker, totaling about $37 million, according to a U.S. Securities and Exchange Commission filing.

The sale comes as part of a plan adopted in March for Huang to sell up to 6 million shares of the leading artificial intelligence company. Huang began trading stock last month. His most recent sale, disclosed last Friday, totaled 225,000 shares, or about $36 million.

Since he began selling stock this year, Huang has unloaded 1.2 million shares, totaling about $190 million, according to InsiderScore. In last year’s prearranged plan, Huang cashed in over $700 million.

AI demand and the need for graphics processing units powering large language models have spiked Huang’s net worth and propelled Nvidia past a $4 trillion market capitalization, making it the most valuable company.

That surge in value has put Huang above Berkshire Hathaway’s Warren Buffett in net worth on Bloomberg’s Billionaire Index.

Read more CNBC tech news

In another significant win, Nvidia said this week that it plans to soon restart sales of its H20 chips to China after the Trump administration indicated that it would approve export licenses.

Earlier this year, the administration said Nvidia would need a license approval to ship the chips, designed specifically for China.

“The U.S. government has assured NVIDIA that licenses will be granted, and NVIDIA hopes to start deliveries soon,” the company said in a statement Tuesday.

Huang said during a press conference on Wednesday in Beijing, China, that he wants to sell chips more advanced than the H20 to China at some point.

Huang wasn’t the only stakeholder to unload Nvidia shares. Board member Brooke Seawell sold $16 million worth of stock.

WATCH: H20 news should add 10% to Nvidia’s street estimates, says Deepwater’s Gene Munster

H20 news should add 10% to Nvidia’s street estimates, says Deepwater's Gene Munster

Continue Reading

Technology

Nvidia CEO Jensen Huang wants to sell more advanced chips to China after H20 ban is lifted

Published

on

By

Nvidia CEO Jensen Huang wants to sell more advanced chips to China after H20 ban is lifted

Jensen Huang, chief executive officer of Nvidia Corp., speaks to members of the media in Beijing, China, on Wednesday, July 16, 2025.

Na Bian | Bloomberg | Getty Images

Nvidia is looking to ship more advanced chips to China than its current generation, CEO Jensen Huang said on Wednesday, as he looks to revitalize sales in the world’s second-largest economy.

The comments come after Nvidia said on Monday that it will resume sales of its H20 artificial intelligence chip to China, reversing a previous ban. The H20 is a less-advanced semiconductor designed for AI workloads that comply with U.S. export restrictions to China.

“I hope to get more advanced chips into China than the H20,” Huang said during a press conference in Beijing, China, in response to a CNBC question.

“And the reason for that is because technology is always moving on … today Hopper’s terrific but some years from now we will have more and more and better and better technology, and I think it’s sensible that whatever we’re allowed to sell in China will continue to get better and better over time as well,” he said referencing Hopper, Nvidia’s chip architecture that the H20 is built on.

Nvidia has been caught in the crosshairs of U.S.-China tensions over trade and technology. The tech giant has faced several rounds of restrictions that have forced it to restrict access of its most advanced chips to China. In response, Nvidia has developed semiconductors that comply with export restrictions, such as the H20.

Nvidia took a $4.5 billion writedown on the unsold H20 inventory in May and said sales in its last financial quarter would have been $2.5 billion higher without any export curbs.

Huang has trod a fine line between praising U.S. President Donald Trump’s policies regarding reshoring chip manufacturing to America while also lobbying for change on curbs to China.

If all the AI developers are in China, the China stack is going to win, Nvidia CEO tells CNBC

The Nvidia boss has argued the Chinese AI market could be worth $50 billion in the next two-to-three years and that it would be a “tremendous loss” for American firms not to be part of that. Huang also told CNBC this year that Nvidia’s Chinese rival Huawei has “got China covered” if U.S. firms can’t participate in the market.

“Export control are things that are outside of our control and they can be quite disruptive to our business. It is our job only to inform the governments of the nature and the unintended consequences of the policies that they make,” Huang said during his visit to Beijing.

Nvidia has also laid out a roadmap to release more advanced chips, though it remains unclear if the U.S. government would allow Nvidia to sell more advanced products to Chinese companies. However, U.S. Commerce Secretary Howard Lutnick suggested on Tuesday that the government would continue to allow chip sales to China so that companies in the market rely on American technology.

“The idea is the Chinese are more than capable of building their own,” Lutnick told CNBC. “You want to keep one step ahead of what they can build, so they keep buying our chips.”

Continue Reading

Trending